Zevra Therapeutics (ZVRA) Non-Current Assets (2014 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of Non-Current Assets data on file, last reported at $48.6 million in Q1 2026.

• Quarterly Non-Current Assets fell 46.66% year-over-year to $48.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $185.3 million (down 48.37% YoY) and the FY2025 annual result came in at $61.7 million, down 32.98% from the prior year.
• Non-Current Assets declined to $48.6 million in Q1 2026, from $61.7 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $92.1 million in Q3 2024 to a low of -$105.8 million in Q1 2022.
• A 5-year average of $35.7 million and a median of $45.0 million in 2025 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2022 — Non-Current Assets sank 4009.09% — and 2024, when it jumped 4577.96%.
• Tracing ZVRA's Non-Current Assets over 5 years: stood at $22.5 million in 2022, then soared by 279.41% to $85.4 million in 2023, then rose by 7.86% to $92.1 million in 2024, then tumbled by 32.98% to $61.7 million in 2025, then decreased by 21.24% to $48.6 million in 2026.
• The last three Non-Current Assets figures came in at $48.6 million (Q1 2026), $61.7 million (Q4 2025), and $45.0 million (Q3 2025), per Business Quant data.